The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

Takayasu Arteritis (TAK) is a large-vessel vasculitis that preferentially involves the aorta and
its primary branches. Cardiac involvement is frequent in TAK and is a major determinant of …

Large-and small-vessel vasculitis are complex potentially life-threatening systemic
autoimmune diseases that have recently been subjected to considerable immunologic and …

Takayasu Arteritis (TAK) is a rare large vessel vasculitis affecting the aorta and its major
branches. The heterogeneous and often severe clinical manifestations result from systemic …

Objective This study aimed to compare the efficacy and safety of adalimumab (ADA) vs
tocilizumab (TCZ) in patients with Takayasu arteritis (TAK). Methods This was a randomized …

Objective To systematically review the measurement properties of outcome instruments
used in large-vessel vasculitis (LVV). Methods MEDLINE, Embase, Cochrane, and Scopus …

Takayasu arteritis (TA or TAK) is a chronic large vessel vasculitis with predilection to affect
the aorta and its branches. The new 2022 ACR/EULAR classification criteria for Takayasu …

The primary vasculitides constitute a heterogeneous group of immune mediated diseases of
incompletely understood pathogenesis currently classified by the size of blood vessels …

Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are large-vessel vasculitides affecting
the aorta and its branches. Arterial damage from these diseases may result in ischemic …

Takayasu arteritis (TA) is a rare, chronic, inflammatory vasculitis that primarily affects large
arteries, causing significant morbidity and mortality. This review provides an overview of the …